Head of Precision Diagnostics

Position: Head of Precision Diagnostics - US
IBEX is a well-funded start-up with a global presence and headquarters in the USA and Israel. Ibex develops state-of-the-art artificial intelligence solutions for cancer diagnostics. Our cutting-edge technology is transforming the diagnosis of cancer, leading to rapid and accurate decision-making and providing new diagnostic insight to enable precision medicine.

Our world-class team of researchers, engineers, and medical experts is growing. If you are an outstanding professional, passionate about your work, a team player, and want to make a difference in the lives of millions of people - come join us. You will get the opportunity to work on novel and challenging problems and help us fight cancer while doing it!

About the Role:

The Head of Precision Diagnostics will be a pivotal leader responsible for driving the growth of Ibex's biopharma business by identifying, shaping, and securing high-value strategic partnerships. This role demands a rare blend of deep clinical credibility and sharp market strategy rooted in precision medicine. Acting as the intellectual engine of our Biopharma business, you will translate complex clinical needs into AI-driven solutions, map out high-potential pharma pipelines, and lead the scientific and strategic engagement.

Utilizing your deep expertise in oncology biomarkers and companion diagnostics (CDx), you will align Ibex's capabilities with pharma drug development and commercialization needs. The ultimate measure of success for this role is accelerating pipeline velocity and successfully securing strategic partnerships and commercial deals with biopharma companies.

Key Responsibilities:

Strategic Alliances & Deal Generation

* Secure Strategic Partnerships:
Drive the end-to-end strategic engagement process with biopharma, from identifying key stakeholders to translating clinical needs into structured opportunities, with the ultimate goal of securing commercial deals.

* Market & Pipeline Mapping:
Systematically analyze the biopharma landscape, clinical trials, and drug pipelines to identify the assets, oncology targets, and companies that have the highest strategic need for Ibex's AI precision diagnostic and biomarker capabilities.

* Scientific Positioning & Value Proposition:
Define and articulate scientifically robust use cases that demonstrate how Ibex's AI accelerates oncology biomarker development, patient stratification, and companion diagnostic (CDx) strategies.

* Thought Leadership:
Position Ibex and its leadership as premier thought leaders in the AI precision diagnostics space by representing the company at major industry conferences, symposia, and digital platforms.

Product Strategy & Cross-Functional Alignment

* Capture Voice of Customer (VOC):
Directly engage with biopharma partners to deeply map their pain points, clinical workflow challenges, and biomarker discovery needs.

* Asset Optimization & Solution Building:
Formulate immediate, high-value offerings leveraging Ibex's existing AI assets while building structured business cases for these solutions.

* Future Product Roadmap Guidance:
Act as the internal strategic bridge for the biopharma segment; identify future technological requirements based on market gaps, translating them into actionable feedback for internal R&D teams to expand Ibex's core capabilities.

* Competitive Intelligence:
Maintain an exhaustive, real-time understanding of the competitive landscape, ensuring Ibex's offerings remain highly differentiated.

* Scientific Publication

Roadmap:

Partner closely with Ibex's internal clinical and medical teams to build and drive a strategic roadmap of scientific publications. This involves identifying key data generation opportunities that validate the clinical utility of Ibex's AI solutions, effectively positioning the company as the premier clinical partner of choice for biopharma organizations.

* Regulatory Contribution:
Collaborate with internal regulatory teams to contribute to the overarching regulatory strategy for the biopharma business, specifically regarding companion diagnostic (CDx) development pathways.